JP2008523102A - Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用 - Google Patents

Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用 Download PDF

Info

Publication number
JP2008523102A
JP2008523102A JP2007545718A JP2007545718A JP2008523102A JP 2008523102 A JP2008523102 A JP 2008523102A JP 2007545718 A JP2007545718 A JP 2007545718A JP 2007545718 A JP2007545718 A JP 2007545718A JP 2008523102 A JP2008523102 A JP 2008523102A
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
substituted
amino
pde4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007545718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008523102A5 (enExample
Inventor
ビー． ゼルディス ジェロメ
イー． ダブリュ． ロハネ パトリシア
エイチ． スチャフェル スチャフェル ペテル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2008523102A publication Critical patent/JP2008523102A/ja
Publication of JP2008523102A5 publication Critical patent/JP2008523102A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
JP2007545718A 2004-12-13 2005-12-12 Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用 Abandoned JP2008523102A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63498204P 2004-12-13 2004-12-13
PCT/US2005/045071 WO2006065814A1 (en) 2004-12-13 2005-12-12 Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation

Publications (2)

Publication Number Publication Date
JP2008523102A true JP2008523102A (ja) 2008-07-03
JP2008523102A5 JP2008523102A5 (enExample) 2009-02-12

Family

ID=36121316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007545718A Abandoned JP2008523102A (ja) 2004-12-13 2005-12-12 Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用

Country Status (13)

Country Link
US (1) US20060148882A1 (enExample)
EP (1) EP1838294A1 (enExample)
JP (1) JP2008523102A (enExample)
KR (1) KR20070092276A (enExample)
CN (1) CN101111235A (enExample)
AR (1) AR052047A1 (enExample)
AU (1) AU2005316593A1 (enExample)
BR (1) BRPI0519030A2 (enExample)
CA (1) CA2590903A1 (enExample)
IL (1) IL183858A0 (enExample)
MX (1) MX2007006992A (enExample)
WO (1) WO2006065814A1 (enExample)
ZA (1) ZA200705540B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523817A (ja) * 2010-04-07 2013-06-17 セルジーン コーポレイション 呼吸器ウイルス感染症の治療方法
JP2014505054A (ja) * 2011-01-10 2014-02-27 セルジーン コーポレイション シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの経口剤形
JP2014511393A (ja) * 2011-03-07 2014-05-15 セルジーン コーポレイション イソインドリン化合物を用いた疾患の治療方法
JP2015164928A (ja) * 2009-02-10 2015-09-17 セルジーン コーポレイション 結核の治療、予防及び管理のためのｐｄｅ４モジュレーターの使用法及び含有組成物
JP2019528298A (ja) * 2016-08-22 2019-10-10 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｐｄｅ４阻害剤

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
ZA200609228B (en) * 2004-04-23 2008-05-28 Celgene Corp Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
AU2010246749B8 (en) 2009-05-14 2014-03-20 Ganzhou Hemay Pharmaceutical Co., Ltd Thiophene derivatives
CA2821805A1 (en) 2010-12-16 2012-06-21 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
AU2012205809B2 (en) * 2011-01-10 2015-09-10 Amgen (Europe) GmbH Phenethylsulfone isoindoline derivatives as inhibitors of PDE 4 and/or cytokines
US9272035B2 (en) 2011-04-28 2016-03-01 Celgene Corporation Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
CN105050624A (zh) 2013-03-14 2015-11-11 细胞基因公司 利用阿普斯特来治疗银屑病关节炎的方法
EP3096749B1 (en) * 2014-01-24 2019-05-15 Celgene Corporation Methods for the treatment of obesity using apremilast
US10092541B2 (en) 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
WO2017030892A1 (en) 2015-08-14 2017-02-23 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
CN110291065B (zh) * 2017-02-28 2022-08-19 康朴生物医药技术（上海）有限公司 一种新的异二氢吲哚衍生物、其药物组合物及应用
EP3595649B1 (en) * 2017-03-16 2025-10-01 Takeda Pharmaceutical Company Limited 5-((2r,4ar,10br)-9-ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)1-methyl-1h-pyridin-2-one for use in the treatment of idiopathic pulmonary fibrosis
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7354948B2 (en) * 2002-11-06 2008-04-08 Celgene Corporation Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
CN1738613A (zh) * 2002-11-18 2006-02-22 细胞基因公司 包含(+)－3－(3,4－二甲氧基－苯基)－3－(1－氧代－1,3－二氢－异吲哚－2－基)－丙酰胺的组合物及其使用方法
WO2004060313A2 (en) * 2002-12-30 2004-07-22 Celgene Corporation Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
ZA200609228B (en) * 2004-04-23 2008-05-28 Celgene Corp Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
CA2565446A1 (en) * 2004-05-05 2005-12-01 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015164928A (ja) * 2009-02-10 2015-09-17 セルジーン コーポレイション 結核の治療、予防及び管理のためのｐｄｅ４モジュレーターの使用法及び含有組成物
JP2013523817A (ja) * 2010-04-07 2013-06-17 セルジーン コーポレイション 呼吸器ウイルス感染症の治療方法
JP2014505054A (ja) * 2011-01-10 2014-02-27 セルジーン コーポレイション シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの経口剤形
JP2014511393A (ja) * 2011-03-07 2014-05-15 セルジーン コーポレイション イソインドリン化合物を用いた疾患の治療方法
JP2019528298A (ja) * 2016-08-22 2019-10-10 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｐｄｅ４阻害剤
JP7029444B2 (ja) 2016-08-22 2022-04-07 メッドシャイン ディスカバリー インコーポレイテッド Ｐｄｅ４阻害剤

Also Published As

Publication number Publication date
ZA200705540B (en) 2009-01-28
WO2006065814A1 (en) 2006-06-22
AU2005316593A1 (en) 2006-06-22
IL183858A0 (en) 2007-10-31
US20060148882A1 (en) 2006-07-06
CA2590903A1 (en) 2006-06-22
BRPI0519030A2 (pt) 2008-12-23
KR20070092276A (ko) 2007-09-12
CN101111235A (zh) 2008-01-23
EP1838294A1 (en) 2007-10-03
MX2007006992A (es) 2007-08-03
AR052047A1 (es) 2007-02-28

Similar Documents

Publication Publication Date Title
JP2008523102A (ja) Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用
US20050239867A1 (en) Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
KR20060125763A (ko) 통증의 치료, 변형 및 관리를 위한 선택적인 사이토킨 억제약물을 포함하는 조성물 및 이의 사용 방법
JP2015164928A (ja) 結核の治療、予防及び管理のためのｐｄｅ４モジュレーターの使用法及び含有組成物
KR20070010184A (ko) 폐 고혈압증의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 상기 화합물을 포함하는 조성물
US20060106085A1 (en) Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
EP1744748A2 (en) Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes
US20070207121A1 (en) Methods of Using and Compositions Comprising Selective Cytokine Inhibitory Drugs for Treatment and Management of Macular Degeneration
US20070161696A1 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US10682336B2 (en) PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
HK1112197A (en) Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation
HK1103989A (en) Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
JP2007524656A (ja) 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法
JP2016540041A (ja) Ｐｄｅ４モジュレーターによるウイルス性疾患の治療のための組成物及び方法
MXPA06004622A (en) Cytokine inhibitory drugs for treatment of macular degeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081211

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20101008